Abstract:Sarah A Norring, &ast Michael G Spigarelli &ast PsyBio Therapeutics, Inc., Sunrise, FL, USA &astThese authors contributed equally to this work Correspondence: Sarah A Norring, Director of Program Management for PsyBio Therapeutics, Inc., 3130 N Pine Island Road, Sunrise, FL, 33351, USA, Tel +1 813 390 1488, Email Introduction: Psilocybin, a tryptamine psychedelic, has been touted in the media both historically and recently as a potential game-changing mental health therapeutic. ClinicalTrials.gov has over one hundred and thirty psilocybin clinical trials listed covering the last twenty years. The single most important aspect of any therapeutic is to gain approval for marketing and thus enter the real-world phase of development. A typical new chemical entity progresses from inception to US Food and Drug Administration (FDA) approval in approximately 12 years and seeks approval for a single indication. Methods: An observational study was conducted with the available information on the ClinicalTrials.gov site to observe the extent of progress made demonstrating the clinical utility of psilocybin. Results: The results showed 134 psilocybin trials typically unblinded studies of 10– 20 participants, recruited over years at a single site. Additionally, there have been only three advanced trials (1 Phase 2/3 and 2 Phase 3) submitted, and only in the last two years. Discussion: The hundreds of psilocybin clinical trials initiated over the past twenty years comprising a myriad of potential indications may actually be slowing this potential game-changing mental health therapeutic agent's approval and is costing excessive amounts of capital. To fully evaluate the actual potential of psilocybin, purposeful clinical trials need to be designed well, executed efficiently, and analyzed utilizing sequential and statistically valid processes for each potential indication. This will require a change from the current exploratory forays to defined, well-funded, sequential pharmaceutical development practices, including adequate and appropriate blinding of studies, statistical design to determine the number of participants and more importantly, professional expertise in conducting multicenter trials. Unfortunately, these results demonstrate little real progress towards FDA approval of psilocybin and a field with no clear direction forward. Keywords: psilocin, psychedelic, FDA approval, mental health Psilocybin, a naturally occurring tryptamine psychedelic found in numerous genera of mushrooms, has been the subject of intense media and popular culture discussion. 1 Hallucinogenic mushrooms have been consumed for millennia around the globe, historically in religious or healing ceremonies. More recently, from the late 1890s through the 1960s, a plethora of hallucinogens isolated and/or chemically synthesized including psilocybin have been described, and human studies were conducted with these hallucinogens for potential treatment of depression and schizophrenia. Psilocybin was evaluated by Sandoz Pharmaceutical company as a psycho-therapeutic drug. 2–4 The Federal Comprehensive Drug Abuse Prevention and Control Act of 1970, more commonly known as the Controlled Substances Act, was enacted to address the registration and distribution of controlled substances in the United States secondary to fear of widespread public utilization of psychedelic substances. As a result of this legislation, psychedelics, then referred to as hallucinogens, were placed under US Drug Enforcement Agency (DEA) Schedule 1, defined as drugs with no currently accepted medical use and a high potential for abuse, and manufacture and use of these psychedelics was severely limited. 5 These newly introduced limitations upon psychedelics resulted in a virtual pause in any research for decades, until a small research resurgence began in the 1990s, and subsequent push towards clinical trial evaluation of these potentially useful compounds. One analysis report describes the psychedelic drugs market size as projected to reach $10.75 Billion by 2027, while growing at a Compound Annual Growth Rate (CAGR) of 12.36% during 2021–2027. 6 To help understand the scope of this clinical research and begin to explore the progress made towards understanding the clinical utility of psilocybin within the confines of regulatorily required data submitted to ClinicalTrials.gov, this retrospective study of clinical trial information listed on ClinicalTrials.gov involving psilocybin was conducted. US National Library of Medicine's ClinicalTrials.gov is a website and online database of clinical research studies and information about their results. The purpose of ClinicalTrials.gov is to provide information about clinical res -Abstract Truncated-

Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions

Acute Adverse Effects of Therapeutic Doses of Psilocybin

Psychedelic mushroom-containing chocolate exposures: Case series

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017–2022

Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022

Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada

The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov

Mental and Behavioral Disorders Associated with the Use of Psychoactive Substances and Alcohol: An Epidemiological Analysis in Southern Brazil

Psilocybin Exposures Reported to US Poison Centers: National Trends Over a Decade

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022)

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals

A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient

The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics

Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States

The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Psychedelic risks and benefits: A cross-sectional survey study